CJC-1295 no DAC / Modified GRF (1-29)
A short-acting modified GHRH (1-29) analogue commonly marketed as CJC-1295 no DAC; distinct from albumin-binding CJC-1295 with DAC.
- Identity
- CJC-1295 no DAC / Modified GRF (1-29)
- Class
- GHRH Analogues
- Published
- 2026-07-16
- Last reviewed
- 2026-08-07
Identity
Modified GRF (1-29) is a stabilized analogue of the active 29-amino-acid fragment of growth hormone-releasing hormone. Commercial pages often call it CJC-1295 no DAC, but that label can blur its distinction from albumin-binding CJC-1295 with DAC.
Mechanism
It acts at the GHRH receptor upstream of pituitary GH release and lacks the drug affinity complex used to extend albumin binding. Multi-day pharmacokinetic findings for CJC-1295 DAC therefore cannot be assigned to no-DAC material.
Evidence Boundary
Human research supports GHRH physiology, but dedicated outcome trials for products marketed under the no-DAC name are sparse. Endocrine activity does not establish durable body-composition, functional, disease or aging outcomes.
Regulatory and Sport Status
No Modified GRF (1-29) product is FDA approved for general wellness, bodybuilding, recovery or weight loss. WADA prohibits growth hormone-releasing factors.
Evidence Gaps
- No approved therapeutic indication.
- No direct clinical outcome comparison with CJC-1295 DAC.
- Limited long-term safety and product-quality data.